The COVID-19 pandemic highlighted the potential role of monoclonal antibodies (mAbs) in tackling a leading infectious disease of global relevance; however, it also highlighted persistent challenges to mAbs access and impact related to emerging variants, high price, challenging administration requirements, and the lack of equitable global access. In the HIV space, the results from the Antibody Mediated Prevention trials provided proof of concept of the potential role of antibodies in HIV prevention, however, the AMP trials also underscored the need for combinations of antibodies that can prevent viral escape, potentially increasing known hurdles related to antibody cost and delivery. With an expanding HIV prevention pipeline and complexities in ensuring global access to mAbs, why should we remain excited about their important contribution to the HIV prevention toolbox? This session will bring together global experts and leaders to discuss innovations and emerging evidence to answer this critical question. The format will combine brief introductory comments from speakers on designated topics, as articulated below, to set the stage for a rich discussion on progress, potential challenges, and critical enablers of broad impact from the monoclonal antibodies.

• Presentations
• Session recording (English)